

# Psychedelics

## Table of Contents

Volume 1 • Number 2 • March 2025

### EDITORIAL

Counting the uncountable: The critical quest to quantify psychedelic medicine's reach

*Julio Licinio* ..... 1

### INNOVATORS & IDEAS: RISING STAR

Alaina M. Jaster: Bridging the gap across preclinical and clinical disciplines in the psychedelic sciences

*Alaina M. Jaster* ..... 3

Fayzan Rab: What are the economic and public health implications of psychedelic therapies?

*Fayzan Rab* ..... 6

### INNOVATORS & IDEAS: RESEARCH LEADER

Charles L. Raison: Elucidating the role of conscious experience in the therapeutic effects of psychedelics as a means to optimize clinical outcomes

*Charles L. Raison* ..... 10

### COMMENTARY

Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression

*Rodolfo Myronn de Melo Rodrigues* ..... 13

### THOUGHT LEADERS INVITED REVIEW

Effects of ayahuasca on fear and anxiety: cross-talk between 5HT1A and 5HT2A receptors

*Lorena Terene Lopes Guerra, Rafael Guimarães dos Santos, and Jaime Eduardo Cecilio Hallak* ..... 15

### RESEARCH REPORT

An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States

*Syed F. Rab, Charles L. Raison, and Elliot Marseille* ..... 26

What motivates spiritual health practitioners in psychedelic-assisted therapy? A qualitative study and implications for facilitator training practices

*Ishan Pasricha, Roman Palitsky ... Deanna M. Kaplan* ..... 31

### Cover Art

An urban twilight scene depicting the intersection of modern society and psychedelic medicine's emergence into mainstream healthcare. The glowing digital display showing "5.1M" symbolizes the mid-range estimate of 5.1 million patients with major depressive disorder who could potentially benefit from psilocybin-assisted therapy according to research findings. The cityscape at dusk—with its gradient purple-orange sky and illuminated buildings—represents the transitional period in which psychedelic treatments are moving from experimental research into regulated medical practice. The taxi in the foreground suggests the journey toward new therapeutic destinations, while the various digital screens and urban elements reflect the complex healthcare system through which novel treatments must navigate. This visualization connects to the paper "An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States" by Syed F. Rab et al. on pages 26-30 in this issue, which analyzes potential patient populations for this emerging treatment modality.

Cover design generated through extensive and iterative human-AI collaboration using Claude by Anthropic and Grok (created by xAI) AI assistants. The final cover is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). This cover may be reproduced without permission under the terms of this license, provided appropriate credit is given to Genomic Press and the content is not modified or used for commercial purposes.

Copyright © 2025 Genomic Press. All rights reserved.

This issue is now available at <https://url.genomicpress.com/6rarafbd>.